The effect of hemolysis on plasma oxidation and nitration in patients with sickle cell disease

Free Radical Research

Volumn 46, Issue 7, 2012, Pages 883-890

  Kupesiz, Alphan ^a   Celmeli, Gamze ^a   Dogan, Serdar ^a   Antmen, Bulent ^b   Aslan, Mutay ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Haemolysis; Nitric oxide; Oxidation; Plasma; Sickle cell disease

Indexed keywords

3 NITROTYROSINE; 8 ISOPROSTANE; BILIRUBIN; CARBONYL DERIVATIVE; HAPTOGLOBIN; HEMOGLOBIN; HEMOGLOBIN A; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME; NITRATE; NITRIC OXIDE; NITRITE;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD CHEMISTRY; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LINEAR REGRESSION ANALYSIS; LIPID OXIDATION; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; NITRATION; OXIDATION; PLASMA CELL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; RETICULOCYTE COUNT; SICKLE CELL ANEMIA;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BILIRUBIN; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DINOPROST; ERYTHROCYTE INDICES; FEMALE; HAPTOGLOBINS; HEMOGLOBIN A; HEMOGLOBIN, SICKLE; HEMOLYSIS; HUMANS; ISOENZYMES; L-LACTATE DEHYDROGENASE; MALE; NITRIC OXIDE; OXIDATION-REDUCTION; RETICULOCYTE COUNT; RETICULOCYTES; TYROSINE;

EID: 84862161610     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2012.686037     Document Type: Article

References (60)

1. Nur E, Biemond BJ, Otten HM, Brandjes DP, Schnog JJ. CURAMA Study Group Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. Am J Hematol 2011;86:484-489.
2. Zhou Z, Behymer M, Guchhait P. Role of extracellular hemoglobin in thrombosis and vascular occlusion in patients with sickle cell anemia. Anemia 2011;2011:918916.
3. Dhaliwal G, Cornett PA, Tierney LM Jr. Hemolytic anemia. Am Fam Physician 2004;69:2599-2606.
4. Aslan M, Freeman BA. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease-mechanisms and consequences. Cell Mol Biol (Noisy-le-grand) 2004;50:95-105.
5. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, Schechter AN, Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002;8:1383-1389.
6. Aslan M, Thornley-Brown D, Freeman BA. Reactive species in sickle cell disease. Ann N Y Acad Sci 2000;899:375-391.
7. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 2001;98:15215-15220.
8. Houston M, Estevez A, Chumley P, Aslan M, Marklund S, Parks DA, Freeman BA. Binding of xanthine oxidase to vascular endothelium: kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem 1999;274:4985-4994.
9. Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J 2005;19:989-991.
10. Wood KC, Hebbel RP, Lefer DJ, Granger DN. Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease induced microvascular dysfunction. Free Radic Biol Med 2006;40:1443-1453.
11. Aslan M, Freeman BA. Redox-dependent impairment of vascular function in sickle cell disease. Free Radic Biol Med 2007;43:1469-1483.
12. Gibson Q, Roughton FJW. The kinetics and equilibria of the reactions of nitric oxide with sheep hemoglobin. J Physiol (London) 1957;136:507-526.
13. Herold S, Exner M, Nauser T. Kinetic and mechanistic studies of the NO-mediated oxidation of oxymyoglobin and oxyhemo-globin. Biochemistry 2001;40:3385-3395.
14. Liu X. Diff usion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem 1998;273:18709-18713.
15. Bensinger TA, Gillette PN. Hemolysis in sickle-cell disease. Arch Intern Med 1974;133:624-631.
16. Langlois MR, Delanghe JR. Biological and clinical signifi-cance of haptoglobin polymorphism in humans. Clin Chem 1996;42:1589-1600.
17. Bourantas KL, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol 1998;61: 49-54.
18. Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006;107:2279-2285.
19. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, et al. Dysregulated arginine metabolism, hemoly-sis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005;294:81-90.
20. Morris CR, Morris SM Jr, Hagar W, van Warmerdam J, Claster S, Kepka-Lenhart D, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-69.
21. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007;21:37-47.
22. Ou CN, Rognerud CL. Diagnosis of hemoglobinopathies: electrophoresis vs. HPLC. Clin Chim Acta 2001;313:187-194.
23. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376: 2018-2031.
24. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, et al. hemoglobin in sickle cell anemia. Blood 2011;118:19-27.
25. Nagel RL, Bookchin RM, Johnson J, Labie D, Wajcman H, Isaac-Sodeye WA, et al. Structural bases of the inhibitory eff ects of hemoglobin F and hemoglobin Az on the polymerization of hemoglobin S. Proc Natl Acad Sci USA 1979;76:670-672.
26. Shokrani M, Terrell F, Turner EA, Aguinaga MD. Chromato-graphic measurements of hemoglobin A2 in blood samples that contain sickle hemoglobin. Ann Clin Lab Sci 2000;30: 191-194.
27. Dalibalta S, Ellory JC, Browning JA, Wilkins RJ, Rees DC, Gibson JS. Novel permeability characteristics of red blood cells from sickle cell patients heterozygous for HbS and HbC (HbSC genotype). Blood Cells Mol Dis 2010;45:46-52.
28. Maier-Redelsperger M, L é vy P, Lionnet F, Stankovic K, Haymann JP, Lef è vre G, et al. Strong association between a new marker of hemolysis and glomerulopathy in sickle cell anemia. Blood Cells Mol Dis 2010;45:289-292.
29. Kopperschl ä ger G, Kirchberger J. Methods for the separation of lactate dehydrogenases and clinical signifi cance of the enzyme. J Chromatogr B Biomed Sci Appl 1996;684:25-49.
30. Hillery CA, Panepinto JA. Pathophysiology of stroke in sickle cell disease. Microcirculation 2004;11:195-208.
31. Gladwin MT, Kato GJ. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program 2005;51-57.
32. Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the " hyperhemolysis paradigm " for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol 2011;86:123-154.
33. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639-1644.
34. Mohan JS, Lip GY, Bareford D, Blann AD. Platelet P-selectin and platelet mass, volume and component in sickle cell disease: relationship to genotype. Thromb Res 2006;117:623-629.
35. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, Vera JC, Levy PS. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994;84:643-649.
36. Kinney TR, Sleeper LA, Wang WC, Zimmerman RA, Pegelow CH, Ohene-Frempong K, Wethers DL, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 1999;103:640-645.
37. Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prchal JT. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001;97:3313-3314.
38. Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta + thalassemia. Blood 2001;97:3998-3999.
39. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007;110: 2166-2172.
40. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001;137:398-407.
41. Klings ES, Christman BW, McClung J, Stucchi AF, McMahon L, Brauer M, Farber HW. Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress. Am J Respir Crit Care Med 2001;164:1248-1252.
42. Aslan M, Canatan D. Modulation of redox pathways in neutrophils from sickle cell disease patients. Exp Hematol 2008;36:1535-1544.
43. Stadtman ER, Oliver CN. Metal-catalyzed oxidation of proteins. Physiological consequences. J Biol Chem 1991;266: 2005-2008.
44. Shacter E. Protein oxidative damage. Methods Enzymol 2000;319:428-436.
45. Martins VD, Manfredini V, Peralba MC, Benfato MS. Alpha-lipoic acid modifi es oxidative stress parameters in sickle cell trait subjects and sickle cell patients. Clin Nutr 2009;28:192-197.
46. Oztas Y, Durukan I, Unal S, Ozgunes N. Plasma protein oxidation is correlated positively with plasma iron levels and negatively with hemolysate zinc levels in sickle-cell anemia patients. Int Jnl Lab Hem 2012;34:129-135.
47. Rees DC, Cervi P, Grimwade D, O ' Driscoll A, Hamilton M, Parker NE, Porter JB. The metabolites of nitric oxide in sickle-cell disease. Br J Haematol 1995;91:834-837.
48. Johnson CS, Giorgio AJ. Arterial blood pressure in adults with sickle cell disease. Arch Intern Med 1981;141:891-893.
49. Enwonwu CO, Xu XX, Turner E. Nitrogen metabolism in sickle cell anemia: free amino acids in plasma and urine. Am J Med Sci 1990;300:366-371.
50. Hatch FE, Crowe LR, Miles DE, Young JP, Portner ME. Altered vascular reactivity in sickle hemoglobinopathy. A possible protective factor from hypertension Am J Hypertens 1989;2:2-8.
51. Allon M. Renal abnormalities in sickle cell disease. Arch Intern Med 1990;150:501-504.
52. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 1999;21:518-522.
53. Baldus S, Eiserich JP, Freeman BA. Is . NO news bad news in acute respiratory distress syndrome? Am J Respir Crit Care Med 2001;163:508-510.
54. Kaul DK, Zhang X, Dasgupta T, Fabry ME. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. Am J Physiol Heart Circ Physiol 2008;295:H39-H47.
55. Aslan M, Ryan TM, Townes TM, Coward L, Kirk MC, Barnes S, et al. Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. J Biol Chem 2003;278: 4194-4204.
56. Krajewski ML, Hsu LL, Gladwin MT. The proverbial chicken or the egg? Dissection of the role of cell-free hemoglobin versus reactive oxygen species in sickle cell pathophysiology. Am J Physiol Heart Circ Physiol 2008;295:H4-H7.
57. Maitre B, Habibi A, Roudot-Thoraval F, Bachir D, Belghiti DD, Galacteros F, Godeau B. Acute chest syndrome in adults with sickle cell disease. Chest 2000;117:1386-1392.
58. Lang JD, Figueroa M, Sanders KD, Aslan M, Liu Y, Chumley P, Freeman BA. Hypercapnia via reduced rate and tidal volume contributes to lipopolysaccharide-induced lung injury. Am J Respir Crit Care Med 2005;171:147-157.
59. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002;296:2391-2394.
60. Knowles ME, McWeeny DJ, Couchman L, Thorogood M. Interaction of nitrite with proteins at gastric pH. Nature 1974; 247:288-289.